Evaluation of the efficacy and safety of quetiapine combined with sodium valproate in patients with acute exacerbation of schizophrenia
Objective To explore the clinical efficacy and adverse effect profile of quetiapine combined with sodium valproate in the treatment of schizophrenia.Methods Using a randomized numerical table approach,124 patients with schizophrenia who were admitted to Chengdu Jinxin Psychiatric Hospital from August 2019 to August 2023 were selected and divided into two groups:an observation group(n=62)and a control group(n=62).Patients in the control group were given sodium valproate extended-release tablets,and those in the observation group were given quetiapine on the basis of the control group.After 6 weeks of treatment,the differences in total effective rate,general psychopathology scale,negative symptom scale(SANS),positive symptom scale(SAPS),positive and negative symptom scale(PANSS)and positive and negative combined symptom scale excitability factor scale(PANSS-EC)scores of the two groups were compared,and the differences of serum prolactin(PRL)and cortisol(COR)levels before and after treatment were also compared.The incidence of adverse reactions was compared between the two groups.Results After 6 weeks of treatment,compared with the total effective rate(70.97%(44/62))in the control group,the total effective rate(87.10%(54/62))in the observation group was significantly higher(χ2=4.867,P<0.05).After 6 weeks of treatment,the scores of the General Psychopathology Scale,SANS Scale,SAPS Scale,PANSS Scale,and PANSS-EC Scale in the observation group((20.63±8.25),(12.06±5.16),(11.95±5.14),(41.28±4.51),and(10.54±4.51)points)were lower than the scores in the control group((26.51±9.95),(16.08±8.05),(14.52±6.28),(50.24±4.27),and(13.96±4.96)points(t=12.904,11.094,14.063,20.475,4.012,all P<0.05).The PRL((206.58±26.24)μg·L-1)and COR((38.16±4.81)μg·L-1)levels in the observation group were lower than those in the control group(PRL(254.21±28.65)μg·L-1,COR(43.93±4.21)μg·L-1)(t=9.653,7.108,both P<0.05).There was no statistically significant difference in the incidence of adverse reactions(6.45%(4/62),8.06%(5/62))between the two groups(χ2=0.120,P=0.729).Conclusion Quetiapine combined with sodium valproate treatment can effectively improve the clinical symptoms of acute exacerbations in schizophrenia patients,regulate the endocrine function of patients,and has a good safety profile.
NETL
NSTL
万方数据
